IO Biotech

Company snapshot

IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines based on its T-win® platform. The T-win platform is based on a novel approach to cancer vaccines designed to activate T cells to target both tumor cells and the immune-suppressive cells in the tumor microenvironment. IO Biotech is advancing its lead cancer vaccine

• 16 active pipeline program(s) linked via ClinicalTrials.gov.
• 21 US patent(s) indexed to this assignee profile.
• 16 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for IO Biotech. Not investment advice.

• Peer + 0 momentum

  Galectin Therapeutics

  TA overlap score 32.4

• Peer + 0 momentum

  Bristol Myers Squibb

  TA overlap score 28

• Peer + 0 momentum

  Iovance Biotherapeutics

  TA overlap score 27.2

• Peer + 0 momentum

  Provectus Biopharmaceuticals

  TA overlap score 22.4

• Peer + 0 momentum

  Aptevo Therapeutics

  TA overlap score 21.8

Recent activity

Latest pipeline, patent, and corporate events for IO Biotech.

1. Jun 8, 2026 Clinical update

   SC201 (VICTORIA-01) — Phase 1

2. Jun 8, 2026 Clinical update

   IOB-022/KN-D38 — Phase 2

3. Jun 8, 2026 Clinical update

   IOB-013/KN-D18 — Phase 3

4. Jun 8, 2026 Clinical update

   IO102-IO103 in combination with pembrolizumab — Phase 2

5. Jun 8, 2026 Clinical update

   NRX 194204 — Phase 2

View all clinical trial activity →

• What is IO Biotech?

  IO Biotech is a biotech organization headquartered in copenhagen, DK. It trades on NYSE under ticker IOBTQ. Primary therapeutic focus areas include Melanoma, Previously untreated, unresectable, or metastatic melanoma, advanced/metastatic solid tumors, NSCLC, Lung Cancer Non Small

• Is IO Biotech publicly traded?

  Yes. IO Biotech is listed with ticker IOBTQ on NYSE per SEC EDGAR records linked on this profile.

• What drugs does IO Biotech develop or market?

  We link 8 drug profile(s) where IO Biotech is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/io-biotech#company-drugs.

• What are the latest developments for IO Biotech?

  In the last 12 months our linked public records show 16 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does IO Biotech focus on?

  IO Biotech focuses on Melanoma, Previously untreated, unresectable, or metastatic melanoma, advanced/metastatic solid tumors based on our analysis of their pipeline programs and drug development activities.